ArticlePhysiological reports2026
MicroRNA-15a/16 regulate protein metabolism and are associated with clinical outcomes in pancreatic ductal adenocarcinoma.
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Dysregulated cellular protein metabolism is a key hallmark of pancreatic ductal adenocarcinoma (PDAC). However, much remains to be learned about how this process is regulated in cancerous cells. Here we investigated the role of two co-transcribed microRNA (miRNA) species, miR-15a/16, in regulating cellular protein translation, cell growth, metabolic processes, and clinical features in PDAC. Using cultured PDAC models, we show that overexpression of miR-15a/16 in cancerous cells slows proliferation and attenuates protein synthesis rates. Bioinformatics analysis reveals that these miRNAs target a broad suite of pathophysiological and metabolic pathways, including numerous genes in cancer- and protein-related processes. Finally, using publicly available patient data, we report that miR-15a/16 expression is lower in PDAC tumors and in patients with pancreatitis than in healthy controls, and that high expression of miR-15a/16 in tumors is associated with improved survival in patients. Our results indicate that miR-15a/16 act as regulators of protein metabolism in PDAC, with potential clinical implications for the management of this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.